NY-CONSENSYS
ConsenSys , an industry-leading blockchain software company, today announced the acquisition of Quorum ® , an enterprise-variant of the Ethereum blockchain developed by J.P. Morgan (NYSE: JPM). With the addition of Quorum, ConsenSys now offers a full range of products, services, and support for Quorum, accelerating the availability of features and capabilities—such as digital asset functionality and document management.
J.P. Morgan and ConsenSys are two leading organizations in Enterprise Ethereum and have a long history of collaboration after leading the creation of the Enterprise Ethereum Alliance , helping bring a Mainnet Ethereum client, Hyperledger Besu , to The Linux Foundation, and working together on industry applications built on Quorum, such as komgo and Covantis . Since the launch of Quorum in 2016, ConsenSys and J.P. Morgan have collaborated to make Ethereum the platform of choice for enterprises building secure and customizable business networks at scale.
“The creation of Quorum was a first for J.P. Morgan, both in terms of developing its own blockchain protocol, and open sourcing software for the developer community,” said Umar Farooq, Global Head of Blockchain, J.P. Morgan . “We’re incredibly proud of the usage of Quorum over the past few years and are excited to have ConsenSys as a partner to take the vision forward.”
ConsenSys will merge its existing protocol engineering roadmap with Quorum, leveraging the best of both codebases. All Enterprise Ethereum protocol technology at ConsenSys will fall under the ConsenSys Quorum brand, and developers will have the option to choose their underlying technology stack. Quorum will remain open source and become interoperable with ConsenSys’ other leading blockchain products, such as Codefi’s finance and commerce application suite. J.P. Morgan will be a customer of ConsenSys’ advanced features and services deployed on Quorum.
“Even before the very first block on Ethereum was mined and ConsenSys was formed, we’ve collaborated with J.P. Morgan on Ethereum proofs of concept and production systems. We are enormously excited to onboard Quorum into the ConsenSys Enterprise Ethereum stack, and look forward to unifying our Hyperledger Besu-based Enterprise Ethereum client with Quorum, and supporting all of the Quorum installations globally. We look forward to continuing our multifaceted partnership with J.P. Morgan for many years and ushering in an era of enterprise and mainnet compatibility,” said Joseph Lubin, Founder and CEO of ConsenSys and Co-creator of Ethereum.
In addition to ConsenSys’ acquisition of the Quorum, J.P. Morgan made a strategic investment in ConsenSys to support its mission to help developers build next-generation networks and enable enterprises to launch more powerful financial infrastructure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press release
Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too f
Cinemo Launches Cinemo ICO™, Accelerating the AI-Driven Intelligent Cockpit19.12.2025 11:00:00 CET | Press release
The future of in-car intelligence, delivered today for hyper-personalized, safer, smarter, and more exceptional journeys Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products announces today the launch of its next-generation, AI-powered cockpit solutions - Cinemo ICO™. By bringing agentic AI, Cinemo unlocks a truly intelligent cockpit - connecting vehicles, drivers, passengers, and their digital ecosystems into one seamless, personal and context-aware flow. The first product launched within the Cinemo ICO™ portfolio is Cinemo ICO™ MediaMind, enabling advanced intelligent media discovery. It combines the latest agentic AI technology with Cinemo’s core expertise of providing automotive-grade media management, helping users effortlessly discover the right content for every ride - perfectly matched to their taste, context, and environment. With Cinemo ICO™ MediaMind, the digital media experience evolves: using cutting-edge large la
Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 08:00:00 CET | Press release
Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def
S3NS Announces SecNumCloud Qualification for PREMI3NS, its Trusted Cloud Offering19.12.2025 07:00:00 CET | Press release
PREMI3NS, S3NS’ (pronounced “sense”) trusted cloud offering, has now received ANSSI’s SecNumCloud qualification, meeting the most stringent protection requirements against extraterritorial laws in France and Europe The fruition of the partnership between Thales and Google Cloud enables organizations from the private and public sectors to innovate and transform with one of the broadest ranges of managed services in a trusted cloud environment Early adopters of S3NS include companies from the insurance, manufacturing, healthcare and finance industries S3NS, a subsidiary of Thales in partnership with Google Cloud, today announced that PREMI3NS, its "Trusted Cloud" (Cloud de confiance) offering, has received the SecNumCloud 3.2 qualification delivered by the French National Agency for the Security of Information Systems (ANSSI). Meeting SecNumCloud 3.2’s protection and resilience requirements, which are known as the most demanding ones in France and Europe, it offers immunity from non-Euro
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom